References
- Willems J. L., Buylaert W. A., Lefebvre R. A., Bogaert M. G. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol. Rev. 1985; 37: 165–216
- Montastruc J. L., Rascol A., Montastruc P. Experimental studies on the antihypertensive action of bromocriptine in dogs. J. Pharmacol. 1979; 10: 79–91
- Montastruc J. L., Montastruc P. Antihypertensive action of bromocriptine in neurogenic hypertensive dogs. Arch. Int. Pharmacodyn. 1981; 252: 210–218
- Lokhandwala M. F., Barret R. J. Cardiovascular dopamine receptors: physiological pharmacological and therapeutic implications. J. Auton. Pharmacol. 1982; 2: 189–215
- Montastruc J. L., Gaillard-Plaza G., Montastruc P. Influence of bromocriptine on the pressor responses to afferent nervous stimulation. J. Pharmacol. 1984; 15: 169–176
- Lokhandwala M. F., Barret R. J. Dopamine receptor agonists in cardiovascular therapy. Drug Dev. Res. 1983; 3: 99–310
- Montastruc J. L., Montastruc P. Alpha adrenolytic properties of bromocriptine in dogs. Arch. Int. Pharmacodyn. 1982; 260: 83–90
- Montastruc J. L., Guiol C., Tran M. A., Lhoste F., Montastruc P. Studies on the cardiovascular actions of apomorphine in dogs: central versus peripheral mechanism and role of the adrenal medulla. Arch. Int. Pharmacodyn. 1985; 277: 92–103
- Hilditch A., Drew G. M. Peripheral dopamine receptor subtypes: a closer look. Trends Pharmacol. Sci. 1985; 6: 396–400
- Brown M. J., Macquin I. Is adrenaline the cause of essential hypertension?. Lancet 1981; 2: 1079–1082
- Montastruc J. L., Montastruc P. The role of the adrenal medulla in the antihypertensive action of bromocriptine in neurogenic hypertensive dogs. J. Pharmacol. 1983; 14: 183–187
- Von Euler U. S., Lishajko F. Improved technique for the fluorometric estimation of catecholamines. Acta Physiol. Scand. 1961; 51: 348–356
- Chamontin B., Montastruc J. L., Rascol A. How do we explain the antihypertensive effect of bromocriptine. Arch. Mal. Coeur 1984; 11: 1181–1185
- Rascol O. J., Montastruc J. L. Cardiovascular effects of apomorphine in man: evidence for peripheral mechanisms. Clin. Neuropharmacol. 1986, (in press).
- Montastruc J. L., Chamontin B., Rascol A. Parkinson's disease and hypertension: chronic bromocriptine treatment. Neurology 1985; 35: 1644–1647
- Walden R. J., Hernandez J., Bhattacherjee P., Graham B., Prichard B. N. C. Bromocriptine in the treatment of hypertension. Eur. J. Clin. Pharmacol. 1986; 30: 141–144
- Schmidt M., Imbs J. L. Renal actions of bromocriptine. J. Pharmacol. 1979; 10: 525–532
- Imbs J. L., Schmidt M., Schwartz J. The renal dopaminergic receptors: pharmacological characterization and therapeutic prospects. J. Pharmacol. 1983; 14(suppl. III)5–27
- Montastruc J. L., Chamontin B., Senard J. M., Rascol A. Domperidone in the management of orthostatic hypotension. Clin. Neuropharmacol. 1985; 8: 191–192
- Rostin M., Montastruc J. L., Senard J. M., Chamontin B., Montastruc P. Clinical Pharmacology and basis of treatment of orthostatic hypotension. Therapie 1986, in press
- Corvol P., Bisseliches F., Alexandre J. M., Bohuon C., Heurtault J. P., Menard J., Tcherdakoff Ph., Vaysse J. C., Milliez P. Poussées hypertensives déclenchées par le sulpiride. Sem. Hôp. Paris. 1974; 50: 1265–1269
- Bentley G. A., Copeland I. W. The effect of chronic haloperidol treatment on some cardiovascular parameters in cats. Br. J. Pharmacol. 1985; 86: 737–741